Form 4 for QURE uniQure N.V.
Accepted 2025-03-05 00:00:00 ET · period of report 2025-03-03 · accession 0000904454-25-000180 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-03-05 | 2025-03-03 | QURE | Abi-Saab Walid | Chief Medical Off | A - Grant | $0.00 | +38.0K | 153.3K | +33% | $0 |
| D | 2025-03-05 | 2025-03-04 | QURE | Abi-Saab Walid | Chief Medical Off | S - Sale | $10.29 | -1,350 | 151.9K | -0.9% | -$13.9K |
| D | 2025-03-05 | 2025-03-03 | QURE | Abi-Saab Walid | Chief Medical Off | A - Grant | $0.00 | +66.0K | 66.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2025-03-03 | A | A | 38,000 | $0.00 | 153,253 | D | — | — | (F1) Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest in equal annual installments of 1/3 each, beginning on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such dates. |
| 2 | Common | Ordinary Shares | 2025-03-04 | S | D | 1,350 | $10.29 | 151,903 | D | — | — | (F2) The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person. (F3) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.25 to $10.35. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 3 | Derivative | Stock Option (Right to Buy) | 2025-03-03 | A | A | 66,000 | $0.00 | 66,000 | D | $10.90 · — to 2035-03-03 | 66,000 Ordinary Shares | (F4) The Stock Option vests 25% on the first anniversary of the date of grant, and 6.25% quarterly thereafter until fully vested, subject to the Reporting Person's continued relationship with the Issuer through such dates. |